Will Ribociclib/Ribociclib be included in medical insurance coverage in 2025?

Ribociclib is an oral small molecule targeted drug that belongs to the CDK4/6 inhibitor class and is used to treat certain types of breast cancer , especially for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) patients. The drug's primary indication is in combination with an aromatase inhibitor as initial endocrine therapy in women with locally advanced or metastatic breast cancer. The establishment of this indication provides a new option for the treatment of breast cancer and improves the survival rate and quality of life of patients.

In clinical studies, ribociclib has shown significant improvements in efficacy compared with traditional treatment options, particularly in slowing disease progression. Its mechanism of action is to prevent the proliferation of tumor cells by inhibiting the key regulatory factors of the cell cycleCDK4 and CDK6. This makes ribociclib one of the important drugs currently used to combat HR+ and HER2- breast cancer, especially when patients require endocrine therapy.

Regarding the medical insurance situation, Riboxiclib has been successfully included in China’s medical insurance coverage, which represents the country’s recognition of the drug’s efficacy and consideration of the economic burden on patients. According to relevant information, the common tablet specifications of Riboxil are 200mg, with 63 tablets per box, and the price is about more than 4,000 yuan. Although the price of a single box of drugs is relatively high, the coverage of medical insurance can greatly reduce the financial pressure on patients, allowing more patients in need of such treatment to receive timely and effective medical support.

In general, the launch of Riboxiclib and its inclusion in medical insurance not only provide a new treatment method for patients with hormone receptor-positive, HER2-negative breast cancer, but also bring greater convenience to the patient's treatment process. All this reflects the continued progress of modern medicine in the fight against breast cancer, bringing hope and confidence to patients.

Reference materials:https://us.kisqali.com/